Navigating FDA-Approved EGFR-Targeted Therapies in NSCLC

This discussion focuses on the current landscape of FDA-approved therapies targeting the EGFR pathway in non–small cell lung cancer (NSCLC) and how their approved indications differ across clinical settings. The conversation will explore how factors such as mutation subtype, line of therapy, resistance mechanisms, and disease stage influence treatment selection. Additionally, differences in labeling related to adjuvant, locally advanced, and metastatic disease will be examined, along with safety and tolerability considerations that may guide clinical decision-making. Overall, this segment aims to clarify how approved EGFR-directed therapies fit into modern NSCLC management and support individualized treatment strategies.